Nilesh Kumar

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 51

Top Topics

Vascular Endothelial Growth Factor

Optical Coherence Tomography

Top Venues

Eye (London, England)

Expert opinion on biological therapy

The British journal of ophthalmology

Ocular immunology and inflammation

This page only lists publications with an associated author ORCID identifier.

Publications

Ashish Sharma, Peter K Kaiser, Ramin Tadayoni, Frank G Holz, Luke Nicholson, Clara Vazquez-Alfageme, Sobha Sivaprasad, Taku Wakabayashi, Se Joon Woo, David Sarraf, Nilesh Kumar, Nikulaa Parachuri, Carl D Regillo, Kourous A Rezaei, Arshad M Khanani, Francesco Maria Bandello, Mahesh Shanamugam, Lalit Verma, Mangat Ram Dogra, Muralidhar Ns, Manisha Agarwal, Anat Loewenstein, Baruch D Kuppermann, null null
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (London, England) (2024)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Maria Bandello, Anat Loewenstein, Baruch D Kuppermann
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (London, England) (2024)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Maria Bandello, Anat Loewenstein, Baruch D Kuppermann
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (London, England) 38 (10) (2024)
Ashish Sharma, Taku Wakabayashi, Carl D Regillo, Chui Ming Gemmy Cheung, Anat Loewenstein, Dinah Zur, Dafna Goldberg, Assaf Hilely, Sengul Ozdek, Hüseyin Baran Özdemir, Nikulaa Parachuri, Nilesh Kumar, Baruch D Kuppermann, Francesco Maria Bandello, Francesca Amoroso
Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study. Eye (London, England) (2024)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Maria Bandello, Anat Loewenstein, Baruch D Kuppermann
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (London, England) 38 (10) (2024)
Ashish Sharma, Peter K Kaiser, Ramin Tadayoni, Frank G Holz, Luke Nicholson, Clara Vazquez-Alfageme, Sobha Sivaprasad, Taku Wakabayashi, Se Joon Woo, David Sarraf, Nilesh Kumar, Nikulaa Parachuri, Carl D Regillo, Kourous A Rezaei, Arshad M Khanani, Francesco Maria Bandello, Mahesh Shanamugam, Lalit Verma, Mangat Ram Dogra, Muralidhar Ns, Manisha Agarwal, Anat Loewenstein, Baruch D Kuppermann, null null
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (London, England) (2024)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Maria Bandello, Anat Loewenstein, Baruch D Kuppermann
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (London, England) 38 (10) (2024)
Ashish Sharma, Frank G Holz, Carl D Regillo, K Bailey Freund, David Sarraf, Arshad M Khanani, Caroline Baumal, Nancy M Holekamp, Ramin Tadayoni, Nilesh Kumar, Nikulaa Parachuri, Baruch D Kuppermann, null null, null null, Francesco Bandello, Giuseppe Querques, Anat Loewenstein, Şengül Özdek, Kourous Rezai, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Dinah Zur, Nicolas Yannuzzi, Giulia Corradetti, Peter Kaiser, Assaf Hilely, David Boyer, Aleksandra Rachitskaya, Usha Chakravarthy, Maximilian Wintergerst, Valentina Sarao, Barbara Parolini, Prithvi Mruthyunjaya, Quan Dong Nguyen, Diana DO, Pearse A Keane, Tarek Hassan, Jayanth Sridhar, David Eichenbaum, Dilraj Grewal, Martin Splitzer
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert opinion on biological therapy (2023)
Ashish Sharma, Anat Loewenstein, Nikulaa Parachuri, Nilesh Kumar, Alok Rasal, Francesco Maria Bandello, Baruch D Kuppermann
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge? Eye (London, England) (2023)
Ashish Sharma, Frank G Holz, Carl D Regillo, K Bailey Freund, David Sarraf, Arshad M Khanani, Caroline Baumal, Nancy M Holekamp, Ramin Tadayoni, Nilesh Kumar, Nikulaa Parachuri, Baruch D Kuppermann
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert opinion on biological therapy (2023)
Ashish Sharma, Frank G Holz, Carl D Regillo, K Bailey Freund, David Sarraf, Arshad M Khanani, Caroline Baumal, Nancy M Holekamp, Ramin Tadayoni, Nilesh Kumar, Nikulaa Parachuri, Baruch D Kuppermann, null null
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert opinion on biological therapy (2023)
Ashish Sharma, Anat Loewenstein, Nilesh Kumar, Nikulaa Parachuri, Francesco Maria Bandello, Baruch D Kuppermann
Aflibercept biosimilars - update on the development progress. Eye (London, England) (2023)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Anat Loewenstein, Francesco Maria Bandello, Baruch D Kuppermann
On label bevacizumab for retina: where it stands. Eye (London, England) 36 (5) (2022)
Ashish Sharma, Mineo Kondo, Chiharu Iwahashi, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Anat Loewenstein, Baruch D Kuppermann
Approved biosimilar ranibizumab-a global update. Eye (London, England) (2022)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Maria Bandello, Baruch D Kuppermann
Fear of safety compromise with biosimilar anti-VEGF-perception or truth. Eye (London, England) 36 (11) (2022)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Carl D Regillo, Francesco Maria Bandello, Baruch D Kuppermann
Retina: a unique subspecialty in the biosimilar landscape. Eye (London, England) 36 (6) (2022)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Carl Regillo, Francesco Bandello, Baruch D Kuppermann
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (London, England) (2022)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Baruch D Kuppermann, Anat Loewenstein, Francesco Maria Bandello
Brolucizumab in polypoidal choroidal vasculopathy. Expert opinion on biological therapy 22 (7) (2022)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D Kuppermann
Biosimilar anti-VEGF-Yardsticks to ensure biosimilarity. Eye (London, England) (2022)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Maria Bandello, Baruch D Kuppermann
Immunogenicity: Clouding the Future of Intravitreal Therapy. Ocular immunology and inflammation (2022)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Baruch D Kuppermann, Francesco Maria Bandello, Carl D Regillo
The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. Expert opinion on biological therapy 22 (6) (2022)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Dhatri Karanam, Baruch D Kuppermann, Francesco Maria Bandello, Carl D Regillo
Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye (London, England) (2021)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Maria Bandello, Baruch D Kuppermann, Anat Loewenstein, Carl D Regillo, Usha Chakravarthy
Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 259 (6) (2021)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein, Carl D Regillo, Usha Chakravarthy
Vortex vein anastomosis and pachychoroid-an evolving understanding. Eye (London, England) 35 (6) (2021)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Bharat Saboo, Hridaya Nath Tripathi, Baruch D Kuppermann, Francesco Maria Bandello
Semaglutide and the risk of diabetic retinopathy-current perspective. Eye (London, England) (2021)
Debdulal Chakraborty, Soumen Mondal, Nikulaa Parachuri, Nilesh Kumar, Ashish Sharma
Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye (London, England) (2021)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Baruch D Kuppermann, Francesco Maria Bandello
The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhage. Eye (London, England) (2021)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Baruch D Kuppermann, Francesco Bandello, Carl D Regillo, David Boyer, Quan Dong Nguyen
Brolucizumab-foreseeable workflow in the current scenario. Eye (London, England) 35 (6) (2021)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye (London, England) (2021)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Rohini Sharma, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein
Brolucizumab-another anti-VEGF or beyond. Eye (London, England) 34 (9) (2020)
Jayaprakash Patil, Laxmi Patil, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein, Ashish Sharma
Smartphone based ROP (S-ROP) screening-opportunities and challenges. Eye (London, England) 34 (9) (2020)
Rajwinder Kaur, Harijot Singh, Shallu Samria, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Francesco Bandello, Anat Loewenstein, Yannick Bilong, M Hafeez Faridi, Ashish Sharma
Correction: MII RetCam assisted smartphone-based fundus imaging (MSFI)-a boon for paediatric retinal imaging. Eye (London, England) (2020)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Sonali Singh, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye (London, England) 35 (5) (2020)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein
Brolucizumab and immunogenicity. Eye (London, England) 34 (10) (2020)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Srinivas R Sadda, Giulia Corradetti, Jeffrey Heier, Adam T Chin, David Boyer, Pouya Dayani, Sruthi Arepalli, Peter K Kaiser
Brolucizumab-early real-world experience: BREW study. Eye (London, England) 35 (4) (2020)
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Francesco Bandello, Baruch D Kuppermann, Carl D Regillo
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD). Eye (London, England) 34 (8) (2020)
Ashish Sharma, Nilesh Kumar, Francesco Maria Bandello, Baruch D Kuppermann, Anat Loewenstein, Carl D Regillo
Brolucizumab: the road ahead. The British journal of ophthalmology 104 (12) (2020)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Maria Bandello, Baruch D Kuppermann, Anat Loewenstein, Carl D Regillo, Usha Chakravarthy
Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. The British journal of ophthalmology 105 (2) (2020)
Jay Sheth, Giridhar Anantharaman, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein, Ashish Sharma
Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. Eye (London, England) 34 (9) (2020)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Maria Bandello, Baruch D Kuppermann, Anat Loewenstein, Carl Regillo, Usha Chakravarthy
Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. The British journal of ophthalmology 105 (3) (2020)
Rajwinder Kaur, Harijot Singh, Shallu Samria, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Francesco Bandello, Anat Loewenstein, Yannick Bilong, M Hafeez Faridi, Ashish Sharma
MII RetCam assisted smartphone-based fundus imaging (MSFI)-A boon for paediatric retinal imaging. Eye (London, England) 34 (8) (2020)
Nilesh Kumar, Francesco Bandello, Baruch D Kuppermann, Ashish Sharma
Comment on: 'Recent advances in anterior chamber angle imaging'. Eye (London, England) 34 (10) (2020)
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Rohini Sharma, Francesco Bandello, Baruch D Kuppermann, Anat Loewenstein
Brolucizumab-key learnings from HAWK and HARRIER. Eye (London, England) 34 (8) (2020)
Ashish Sharma, M Hafeez Faridi, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Baruch D Kuppermann, Francesco Bandello, Anat Loewenstein, Carl D Regillo
Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (London, England) 34 (6) (2019)
Ashish Sharma, Nilesh Kumar, Francesco Bandello, Anat Loewenstein, Baruch D Kuppermann
Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye (London, England) 34 (6) (2019)
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Anat Loewenstein, Francesco Bandello
Brolucizumab: is extended VEGF suppression on the horizon? Eye (London, England) 34 (3) (2019)
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Maria Bandello, Anat Loewenstein
Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. The British journal of ophthalmology 104 (1) (2019)
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Bandello
Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye (London, England) 34 (4) (2019)
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Bandello
Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye (London, England) 34 (5) (2019)
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Bandello, Anat Loewenstein
Ophthalmic biosimilars and biologics-role of endotoxins. Eye (London, England) 34 (4) (2019)
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Bandello, Anat Loewenstein
Faricimab: expanding horizon beyond VEGF. Eye (London, England) 34 (5) (2019)